In this open-label trial, a higher proportion of asymptomatic follicular lymphoma patients assigned to rituximab required no further treatment at nearly 15 years compared with those assigned to ...

For patients presenting with moderate to severe pemphigus, the choice of initial therapy has been distilled to a single agent: rituximab. This drug is more rapidly effective, more likely to provide ...

Anti-CD20 B cell-depleting agents such as rituximab may offer a promising initial disease-modifying treatment (DMT) for relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple ...

A phase 3 trial explored which treatment option for pemphigus vulgaris, a rare skin disease, resulted in better outcomes after 52 weeks. In patients with pemphigus vulgaris, rituximab was superior to ...

The pressure is mounting on Roche after Swiss rival Sandoz filed a US biosimilar of cancer and inflammatory diseases drug rituximab, closely behind a rival from Teva and Celltrion. Rituxan (rituximab) ...

Key opportunities in the rituximab biosimilars market include the launch of new biosimilar formulations, expansion of ...

In a new study, rituximab therapy was found to be an effective treatment option for lupus nephritis (LN) management. After six months of use, people with lupus nephritis taking the therapy showed ...

Rituximab demonstrated superiority to azathioprine in a randomized trial. Recent data continue to support the use of rituximab as the standard of care for maintenance therapy for patients with ...

In the RITUXVAS trial, 5 44 patients with newly diagnosed severe AAV with renal involvement from eight centers in Europe and Australia were randomized in a 3:1 ratio to receive a standard ...

To review the clinical efficacy and safety of rituximab for treatment of IgG4-related orbital disease (IgG4-ROD). All cases of IgG4-ROD were either steroid dependent or steroid resistant. Rituximab ...

Rituximab in combination with fludarabine and cyclophosphamide is recommended as a treatment option for people with relapsed or refractory chronic lymphocytic leukaemia except when the condition: is ...